SG Americas Securities LLC raised its stake in Genelux Co. (NASDAQ:GNLX – Free Report) by 45.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 9,605 shares of the company’s stock after purchasing an additional 3,000 shares during the quarter. SG Americas Securities LLC’s holdings in Genelux were worth $135,000 at the end of the most recent reporting period.
A number of other hedge funds have also recently bought and sold shares of the stock. California State Teachers Retirement System bought a new position in shares of Genelux during the 2nd quarter worth approximately $30,000. Amalgamated Bank boosted its stake in shares of Genelux by 250.8% during the 3rd quarter. Amalgamated Bank now owns 1,077 shares of the company’s stock worth $26,000 after acquiring an additional 770 shares during the period. Tower Research Capital LLC TRC bought a new position in shares of Genelux during the 1st quarter worth approximately $32,000. Legal & General Group Plc boosted its stake in shares of Genelux by 535.2% during the 3rd quarter. Legal & General Group Plc now owns 1,696 shares of the company’s stock worth $41,000 after acquiring an additional 1,429 shares during the period. Finally, JPMorgan Chase & Co. lifted its holdings in Genelux by 2,105.0% during the 2nd quarter. JPMorgan Chase & Co. now owns 2,205 shares of the company’s stock worth $72,000 after purchasing an additional 2,105 shares during the last quarter. 37.33% of the stock is currently owned by institutional investors.
Analysts Set New Price Targets
Several analysts recently weighed in on the company. Benchmark reissued a “speculative buy” rating and set a $30.00 price target on shares of Genelux in a report on Wednesday, April 3rd. HC Wainwright dropped their price target on Genelux from $35.00 to $32.00 and set a “buy” rating for the company in a report on Tuesday, April 2nd.
Genelux Price Performance
NASDAQ:GNLX opened at $3.62 on Thursday. The stock has a 50 day simple moving average of $6.36 and a 200 day simple moving average of $11.70. Genelux Co. has a 1-year low of $3.42 and a 1-year high of $40.98.
Genelux Profile
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.
Recommended Stories
- Five stocks we like better than Genelux
- Low PE Growth Stocks: Unlocking Investment Opportunities
- United Airlines Soars on Earnings Beat
- How is Compound Interest Calculated?
- J.B. Hunt Hits the Skids: Lower Prices to Come
- 3 Fintech Stocks With Good 2021 Prospects
- Predicting a Bear Market: 7 Signs and Why it’s Tough to Do
Want to see what other hedge funds are holding GNLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Genelux Co. (NASDAQ:GNLX – Free Report).
Receive News & Ratings for Genelux Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genelux and related companies with MarketBeat.com's FREE daily email newsletter.